BRAF and melanoma: Of note, although the combination of dabrafenib (BRAFi) and trametinib (MEKi) is an established clinical treatment for BRAF-mutant melanoma due to its improved efficacy and delayed resistance, we employed single-agent treatments in our models to dissect their specific resistance mechanisms.